What do systematic reviews say?

R‐salbutamol 0.5% topical cream vs placebo

The review found no eligible studies for this question.

• Drugs for discoid lupus erythematosus 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

R‐salbutamol 0.5% topical cream vs placebo

The review found no eligible studies for this question.

• Drugs for discoid lupus erythematosus 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

R‐salbutamol 0.5% topical cream vs placebo

• Drugs for discoid lupus erythematosus 2017 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 37 participants
  Moderate

Tacrolimus 0.1% cream vs placebo

The review found no eligible studies for this question.

• Drugs for discoid lupus erythematosus 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Tacrolimus 0.1% cream vs placebo

The review found no eligible studies for this question.

• Drugs for discoid lupus erythematosus 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Tacrolimus 0.1% cream vs placebo

The review found no eligible studies for this question.

• Drugs for discoid lupus erythematosus 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Tacrolimus 0.1% cream vs placebo

The review found no eligible studies for this question.

• Drugs for discoid lupus erythematosus 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Tacrolimus 0.1% cream vs placebo

• Drugs for discoid lupus erythematosus 2017 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 14 participants
  Moderate

Itraconazole (200 mg for 6 to 8 weeks) vs placebo

The review found no eligible studies for this question.

• Interventions for Old World cutaneous leishmaniasis 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Itraconazole (200 mg for 6 to 8 weeks) vs placebo

It is very uncertain whether itraconazole (200 mg for 6 to 8 weeks) changes percentage of participants with complete cure compared with placebo (very low certainty).

• Interventions for Old World cutaneous leishmaniasis 2017 · Cochrane Headline outcomes only
  RR 3.7 [0.35, 38.99]
  3 studies · 244 participants
  Very low

Itraconazole (200 mg for 6 to 8 weeks) vs placebo

It is very uncertain whether itraconazole (200 mg for 6 to 8 weeks) changes adverse effects Mild abdominal pain and nausea Adverse effects Mild… compared with placebo (very low certainty).

• Interventions for Old World cutaneous leishmaniasis 2017 · Cochrane Headline outcomes only
  RR 2.36 [0.74, 7.47]
  3 studies · 204 participants
  Very low

Itraconazole (200 mg for 6 to 8 weeks) vs placebo

The review found no eligible studies for this question.

• Interventions for Old World cutaneous leishmaniasis 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Itraconazole (200 mg for 6 to 8 weeks) vs placebo

It is very uncertain whether itraconazole (200 mg for 6 to 8 weeks) changes microbiological or histopathological cure of skin lesions compared with placebo (very low certainty).

• Interventions for Old World cutaneous leishmaniasis 2017 · Cochrane Headline outcomes only
  RR 17 [0.47, 612.21]
  1 study · 20 participants
  Very low

Antibiotic prophylaxis vs no treatment/placebo

Antibiotic prophylaxis probably leads to lower recurrence of cellulitis compared with no treatment/placebo (moderate certainty).

• Interventions for the prevention of recurrent erysipelas and cellulitis 2017 · Cochrane Headline outcomes only
  RR 0.31 [0.13, 0.72]
  5 studies · 513 participants
  Moderate

Antibiotic prophylaxis vs no treatment/placebo

Antibiotic prophylaxis probably leads to lower incidence rate of cellulitis compared with no treatment/placebo (moderate certainty).

• Interventions for the prevention of recurrent erysipelas and cellulitis 2017 · Cochrane Headline outcomes only
  RR 0.44 [0.22, 0.89]
  4 studies · 473 participants
  Moderate

Antibiotic prophylaxis vs no treatment/placebo

Antibiotic prophylaxis probably leads to lower time to next episode of cellulitis compared with no treatment/placebo (moderate certainty).

• Interventions for the prevention of recurrent erysipelas and cellulitis 2017 · Cochrane Headline outcomes only
  HR 0.51 [0.34, 0.78]
  3 studies · 437 participants
  Moderate

Antibiotic prophylaxis vs no treatment/placebo

Antibiotic prophylaxis showed no clear difference in hospitalisation compared with no treatment/placebo (low certainty).

• Interventions for the prevention of recurrent erysipelas and cellulitis 2017 · Cochrane Headline outcomes only
  RR 0.77 [0.37, 1.57]
  3 studies · 429 participants
  Low

Antibiotic prophylaxis vs no treatment/placebo

Antibiotic prophylaxis showed no clear difference in any adverse reactions compared with no treatment/placebo (low certainty).

• Interventions for the prevention of recurrent erysipelas and cellulitis 2017 · Cochrane Headline outcomes only
  RR 0.87 [0.58, 1.3]
  4 studies · 469 participants
  Low

Antibiotic prophylaxis vs no treatment/placebo

The review found no eligible studies for this question.

• Interventions for the prevention of recurrent erysipelas and cellulitis 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Complete cure and adverse events for terbinafine vs placebo

The review found no eligible studies for this question.

• Oral antifungal medication for toenail onychomycosis 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found